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The central neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s 
disease (PD), have been one of the biggest health problems worldwide. Currently, there is no 
cure for these diseases. The Gardenia jasmenoides fruit is a common herbal medicine in 
Traditional Chinese Medicine (TCM), and there are a variety of preparations of Gardenia 
jasminoides fruits used as treatments for central nervous system (CNS) diseases. 
Pharmacokinetic studies suggest that genipin is one of the main effective ingredients of 
Gardenia jasmenoides fruit extract (GFE). Accumulated research data showed that genipin 
possesses a range of key pharmacological properties such as anti-inflammatory activity, 
neuroprotective and neurogenic action, antidepressant effects, and antidiabetic action. Based 
on this, genipin shows therapeutic potential for central neurodegenerative diseases. In the 
present review, we will review the pharmacological actions of genipin for the treatment of 
neurodegenerative diseases of the CNS, and additionally, potential mechanisms underlying its 
effects will also be described. 
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Key points:  
 
- Neurodgenerative diseases pose a serious challenge to world health organisation 
- novel findings suggest that active components from traditional Chinese medicine could help 




As a result of aging populations in the industrialized nations, central neurodegenerative 
diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are one of the 
biggest health problems worldwide. At present, there is no cure or disease- modifying 
treatment for these diseases [1]. As a productive natural resource for drug discovery, 
Traditional Chinese Medicine (TCM) plays an important role in complementary and 
alternative medical systems, and has a great advantage for treatment of chronic diseases due 
to its long history. In oriental countries, TCM has been used to treat CNS diseases for 
thousands of years in clinical practice. However, the molecular mechanisms involved in TCM 
still remain unclear, and it can be challenging to systematically identify these using modern 
pharmacological and biochemical techniques [2]. Gardenia jasmenoides fruit is a classic 
herbal medicine in TCM which needs to be studied in more detail to uncover its molecular 
actions.  
Gardenia jasminoides Ellis (Its Chinese herbal name is Zhi Zi) is an evergreen shrub that 
is mostly distributed in the southern regions of China. Gardenia jasmenoides fruit extract 
(GFE) has been used as an effective oral treatment for inflammation, jaundice and hepatic 
disorders in TCM [3]. It is one of the commonly used herbal medicines or functional food 
supplements in China and other oriental countries [4]. In TCM, there are a variety of 
preparations that contain extracts of Gardenia jasminoides fruits, such as 
Huang-Lian-Jie-Du-Tang [5], Tong-Luo-Jiu-Nao [6], or Xing-nao-jing [7], which have been 
proven to have good therapeutic effects on CNS diseases, including dementia, cerebral stroke, 
and depression [8]. However, the precise pharmacological mode of action of these TCM 
treatments is often unclear, and therefore it is not readily accepted by western modern 
medicine.  
The pharmacokinetic studies suggested that genipin is the main active ingredient of GFE. 
Geniposide is a water-soluble iridoid glycoside component found in Gardenia jasmenoides 
fruit, but geniposide itself is not regarded as a main active ingredients of GFE. It was shown 
that geniposide is hydrolyzed by β-D-glucosidases into genipin in the intestine [9]. Genipin is 
liposoluble, and this feature makes it easy for it to permeate into intestinal mucosa and 
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facilitate absorption. Genipin itself is colorless but it reacts spontaneously with the amino 
groups of amino acids to form blue pigments which are widely used in the food industry. 
Genipin is also used as a crosslinking reagent for biological tissue fixation [10]. Importantly, 
genipin also possesses pharmacological properties such as anti-inflammatory effects [11], 
antiangiogenic[12], antithrombotic [13], anti-diabetic [14], anti-tumor [15], neurotrophic [16] 
and anti-depressive effects [17]. See Fig. 1 for an overview. Until recently, geniposide was 
considered the main active ingredient, but more detailed studies show that it is most likely 
only a precursor of genipin. Therefore, genipin has been in the focus of research as a versatile 
therapeutic agent for multiple diseases, especially central neurodegenerative diseases. In the 
following paragraphs, we will review pharmacological actions of genipin for treatment of 
central neurodegenerative diseases, and potential underlying biochemical mechanisms of 
action will also be highlighted.   
 
2. Anti-inflammatory action of genipin 
A key element of disease progression in neurodegenerative diseases is the development 
of a chronic neuroinflammation response in the brain [18-20]. Elevated concentrations of 
proinflammatory cytokines such as interleukin (IL)-1ß, IL-6, and tumor necrosis factor (TNF) 
have been found in the brain, cerebral spinal fluid, and blood of AD and PD patients [21]. The 
role of the acute immune or inflammatory response is to remove damaged tissue or to 
inactivate potentially damaging agents or invaders. The chronic inflammation response 
becomes neurotoxic due to the production of free radicals and pro-inflammatory cytokines. 
Abnormal production of pro-inflammatory cytokines by activated microglia and astrocyte can 
lead to synapse dysfunction and ultimately synapse loss [22]. Moreover, the chronic 
neuroinflammation response is considered to play a role in promoting the formation of 
pathological protein plaques including amyloid plaque [23] and Lewy bodies [24]. Therefore, 
anti-inflammatory medication could be an effective therapeutic or preventive strategy for 
neurodegenerative diseases [25, 26].  
The Gardenia fruit has been used for the treatment of inflammation in folk medicine for 
centuries in Asian countries, but the underlying mechanism of its activity needs to be 
investigated further. In recent studies, topical and systematic anti-inflamm
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genipin have been confirmed in a variety of animal and cell studies, and some of the key 
pharmacological mechanisms of genipin have been uncovered.  
In a variety of topical inflammatory animal models, genipin has relieved acute 
inflammatory responses. One study showed that genipin inhibited the acute inflammatory 
response in the carrageenan-induced rat paw edema, carrageenan-induced rat air pouch edema 
and croton oil-induced mouse ear edema models [11]. Moreover, genipin inhibited the 
changes in mouse vascular permeability induced by acetic acid [11], and 
concentration-dependently reduced lipid peroxidation induced by Fe2+/ascorbate in rat brain 
homogenate [27]. Hence, the authors believe that genipin, rather than geniposide, is the major 
anti-inflammatory component of the gardenia fruit.  
In several inflammatory cell models, genipin also has shown anti- inflammatory activity, 
and the hypothesis that nitric oxide synthase (NOS) and nuclear factor κB (NF-κB) maybe the 
potent targets of genipin has been proposed. In RAW 264.7, a murine macrophage cell line, 
stimulated by lipolysaccharide (LPS) or interferon, genipin may reduce inflammation by 
inhibiting the expression of inducible nitric oxide synthase (iNOS) and the production of 
nitric oxide (NO), as well as by inhibition of NF-κB activation [27]. Moreover, genipin has 
stronger anti-inflammatory activity than geniposide, and geniposide did not show any 
decreasing effects in the iNOS expression in RAW 264.7 magrophages [11]. In a murine 
microglial cell line named BV-2, genipin also inhibited LPS-induced increases in NO 
production and mRNA levels of inducible NOS (iNOS), COX2, IL-1β and IL-6 [8]. Another 
study demonstrated that genipin can reduce the inflammation response by inhibiting the 
inflammasome activation. This inhibition is dependent on the suppression of autophagy [28]. 
Furthermore, genipin also inhibited LPS-induced inflammatory responses in primary rat 
microglia cells and in the cerebral cortex and hippocampus in mice [29]. Since genipin can 
react with the amino group of amino acids to form stable blue pigments, the 
anti-inflammatory effect of these blue pigments also was confirmed in LPS- stimulated RAW 
264.7 macrophages, and the anti-inflammatory mechanism of these pigments might be same 
as those of genipin [30]. 
Apart from inhibiting NOS, NO and NF-κB expression, other possible mechanisms may 
be involved in the anti-inflammatory properties of genipin. A study demonstrated that 
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inhibition of exocytosis is a novel anti-inflammatory mechanism of genipin [31]. Additionally, 
genipin enhanced the anti-inflammatory response via upregulation of heme 
oxygenase-1(HO-1) in macrophages [32]. Moreover, genipin suppressed the LPS-induced 
inflammation response via newly identified mechanisms, including downregulation of 
chemokines, chemokine receptors, and IFN-induced protein expression [33]. Further systemic 
inflammation studies also have indicated that genipin attenuates mortality and organ injuries 
during sepsis through interference with TLR signaling which is crucial for induction of 
hyperinflammatory responses and tissue injury during sepsis [34]. Genipin also reduced the 
lethality induced by D-galactosamine/LPS-induced fulminant hepatic failure through 
prevention of oxidative stress, apoptosis and NF-κB nuclear translocation [35]. A study also 
showed that genipin exerted its anti-inflammatory effects via activation of the PI3K/Akt 
signaling pathway [36]. 
In conclusion, these findings suggested that genipin might be useful as a potential 
therapeutic agent for the treatment of topical and systematic inflammatory diseases. Genipin 
would be an ideal starting point for the development of a new non-steroidal anti-inflammatory 
drug (NSAID) with fewer side effects. In contrast, geniposide did not show any effects in 
anti-inflammatory activity. Hence, genipin may be a better anti-inflammatory strategy for 
neurodegenerative diseases.   
 
3. Neurotrophic and neuritogenic action of genipin 
Neuronal loss in specific brain regions and synaptic failure are the main causes which 
result in most of the typical symptoms of neurodegenerative diseases. In AD, the basal 
forebrain, the hippocampus and its neighboring cortical structures within the temporal lobe 
lost a large number of neurons, and a reduced acetyl choline (ACH) activation, which is one 
of the reasons for the decline in cognitive ability of AD patients [37]. In PD, the substantia 
nigra loses a large number of dopaminergic neurons, and causes reduced dopamine 
transmission, which is a key element in the decline of motor activity of PD patients [38]. 
Therefore, the therapeutics that can promote neurotrophic processes and neurogenesis to 
remedy neuronal loss will be a promising therapeutic strategy. It is known that the 
physiological roles of neurotrophins on the nervous system span from neuronal development, 
	 7	
to growth, repair, blocking of apoptotic pathways and cell survival. Reduced levels of 
endogenous neurotrophic factors, such as GDNF, NGF and BDNF has been observed in 
several neurodegenerative diseases [39]. Therefore, any drug that has neurotrophic activity 
may play a therapeutic effect in neurodegenerative diseases [40].  
Recently, both neuroprotective and neuritogenic (neurite outgrowth) action of genipin 
have been demonstrated in a series of studies in which the molecular mechanisms of the 
neuritogenic effect of genipin has been defined further [16]. The studies found that genipin 
does not enhance the expression of any endogenous neurotrophic compounds such as NGF or 
other neurotrophins at effective concentrations and that genipin extends neurites without 
activation of any neurotrophin receptors, including the Tropomyosin receptor kinase A 
(TrkA). Indeed, genipin induces neurite outgrowth by activating neuronal NO synthase 
(nNOS), cyclic GMP-dependent protein kinase, and mitogen-activated protein kinase (MAPK) 
in PC12h cells [41] and Neuro2a cells [42]. This suggests that nNOS plays a crucial role in 
the observed neurotrophic activities of genipin, as it has also been reported that genipin has 
structural and electron transferring properties as an activator of nNOS. Genipin also protects 
neuronal cells against cytotoxicity induced by various agents including amyloid-β (Aβ), 
6-hydroxydopamine (6-OHDA), hydrogen peroxide, and endoplasmic reticulum stress 
inducers in vitro [42, 43]. In contrast, the authors found that the precursor geniposide did not 
show any neuroprotective or neuritogenic action. In addition, other studies showed that 
genipin can protect cells against damage from ROS and Reactive Nitrogen Species (RNS) 
production in organotypic hippocampal slice cultures, demonstrating its potential as a free 
radical scavenger [44]. Genipin also significantly reduced cell death due to rotenone exposure, 
providing evidence for genipin's ability to distribute within cells to prevent the widespread 
damage following the internal production of ROS and RNS. These findings suggested that 
genipin may be a novel potential treatment for a range of neurodegenerative diseases.  
Based on these findings, a series of genipin derivatives have been designed and the 
neurotrophic activity of these derivatives has been confirmed to be superior to genipin. 
Gardenamide A (GA) is a stable genipin derivative that was shown to have greater 
neuroprotective effects than genipin in PC12 cells when exposed to serum deprivation and 
6-OHDA exposure. GA attenuated the accumulation of intracellular ROS and the loss of 
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mitochondrial membrane potential. The mechanism was mediated by both the PI3K/Akt and 
ERK1/2 signaling pathways [45]. Some authors claimed that the direct activation on 
endothelial NOS may be the reason for the stronger activity of GA when compared to that of 
genipin [46]. Recently, Koriyama et al. also design a novel long-acting genipin derivative, 
(1R)-isoropyloxygenipin (IPRG001), which showed significant neuroprotective activity in 
RGC-5 cells, a retinal precursor cell line, against oxidative stress, such as hydrogen peroxide 
[47]. Furthermore, IPRG001 promoted staurosporine-induced neurite outgrowth from RGC-5 
cells in a dose-dependent manner [48]. Indeed, both the neuroprotective and neuritogenic 
effects of IPRG001 in RGC-5 cells were all nNOS/NO-dependent. They found that IPRG001 
significantly induced RARb expression in adult rat RGCs through S-nitrosylation of HDAC2 
processing mechanisms. Concomitant with RARb expression, adult rat RGCs displayed a 
regenerative capacity for optic axons in vivo after IPRG001 treatment [49]. Therefore, some 
authors postulated that genipin and its derivative most likely act as neurotrophic factor-like 
compounds with both neuritogenic and neuroprotective effects.  
 
4. Antidepressant effect of genipin 
Depression is a state of low mood and motivation levels that can affect a person's 
thoughts, behavior, feelings and sense of well-being. Depression is common in the 
neurodegenerative diseases [50]. It occurs in approximately 45% of all patients with PD [51] 
and 20-25% of AD patients [52], and is associated with greater impairment of the quality of 
life and an increased caregiver burden. It is hypothesized that depression is a consequence of 
the disease process itself, sometimes developing prior to the onset of motor symptoms or 
cognitive symptoms. Recent studies have suggested that some of the currently available 
antidepressant medications may be effective and well tolerated in PD population [53], and 
clinical trial data support that antidepressants have the potential to treat AD. Antidepressants 
are reported to regulate stem cell fate to regenerate neurons in the adult hippocampus and are 
effective in reducing toxic amyloid peptides and are known to increase neurotrophic factors 
such as the brain-derived neurotrophic factor (BDNF) [54]. 
Our understanding of the pathophysiology of PD and AD associated depression remains 
limited. So far, the pathogenesis of depression is interpreted by two popular hypotheses. One 
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hypothesis is the deficiency of monoamines neurotransmitter serotonin (5-hydroxytryptamine, 
5-HT) which is a key topic in the field of biological psychiatry and which lead to the 
development of tricyclic antidepressants (TCAs), selective norepinephrine reuptake inhibitors 
(SSRIs), monoamine oxidase inhibitors (MAOIs), norepinephrine reuptake dual inhibitors 
(NARIs) and selective norepinephrine reuptake inhibitors (SNRIs) [55, 56]. Another 
hypothesis is the deficiency of neurotrophins, which promotes the external application of 
neurotrophins, such as BDNF, for the treatment depression [57, 58]. However, current 
antidepressant therapies act slowly, and these drugs fail to work for 30% of patients, and can 
cause undesirable side effects as observed in clinical practice [59]. 
In TCM, herb compounds containing G. jasminoides fruits, such as Zhi-zi-chi 
preparations [60], the Yueju pill and others, has been widely used for the treatment of 
depression in East Asian countries for hundreds of years [61]. Recently, the mechanism of 
action of these herb medicines has been gradual uncovered by pharmacological studies. Xue 
and colleagues have found that acute administration of the ethanol extract of the Yueju pill 
rapidly attenuated depressive-like symptoms in learned helpless paradigms, and the 
antidepressant-like effects were sustained for at least 24 hours in tail suspension tests of ICR 
mice. Additionally, the Yueju pill, like ketamine, an antidepressant that blocks NMDA 
receptors, rapidly increased the expression of BDNF in the hippocampus of mice [62, 63]. 
Moreover, other authors also verified that the ethanolic or methanolic extract of G. 
jasminoides fruits can inhibit MAO-A/B and Dopamine β-Hydroxylase activity in in vitro 
assays, and the action of the extract was also observed after oral administration in rats [64]. 
Further research showed that iridoid compounds, geniposide and genipin, are the major 
bioactive ingredients for antidepressant activity in these herb compounds containing G. 
jasminoides fruits. The iridoid compounds could pass through the blood brain barrier (BBB) 
and distribute in the hippocampus, hypothalamus, premotor cortex, striatum, oblongata and 
cerebellum [60]. In addition, iridoid compound show significant selective MAO-B inhibition 
and are more potent than the other isolated compounds.  
The antidepressant effects of genipin have been evaluated in multiple animal models of 
depression. Studies showed that intragastric administration of genipin for 7 days in mice 
significantly reduced the duration of immobility in the forced swimming test and the tail 
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suspension test, while it did not affect the locomotor activity in the open field test. Genipin 
could antagonize reserpine-induced ptosis and hypothermia and elevate the contents of 
norepinephrine (NE) and 5-HT in mice hippocampi significantly [17]. In addition, using 
1H-NMR spectroscopy in a chronic unpredictable mild stress (CUMS) rat model, they found 
that the levels of 5-HT and NE in the hippocampus decreased and the level of 
5-hydroxyindole acetic acid (5-HIAA) increased in the CUMS-induced depressive rats. 
However, pre-treatments with genipin significantly increased the levels of 5-HT, NE and 
decreased the level of 5-HIAA in the hippocampus [65]. Hence, these results suggest that one 
possible mechanism of antidepressant-like effects on genipin is due to the modulation of the 
monoaminergic neurotransmitter system and the potential dysfunctional regulation of the 
post-receptor signaling pathway, which particularly affected the 5-HT1AR, 5-HT2AR and 
BDNF levels in the hippocampus [66]. 
 
5. Anti-diabetic effects of genipin 
The incidence of central neurodegenerative diseases appears to be higher in people with 
T2DM, suggesting that shared mechanisms, such as insulin dysregulation or insulin resistance 
(IR), may underlie these conditions [67]. As a consequence, some anti-diabetic strategies, 
such as insulin [68], metformin [69] and incretin hormones administration [70] are being 
developed to inhibit pathologic hallmarks of neurodegenerative diseases. The extract of 
Gardenia jasminoides Ellis fruits has been used over the years in TCM to treat symptoms of 
T2DM. However, the explicit biological mechanism related to the anti-diabetic effect was not 
known until recently. New studies gave some indications that uncoupling protein 2 (UCP2) 
negatively regulates glucose-stimulated insulin secretion and genipin plays an anti-diabetic 
role by inhibiting UCP2 [14].  
UCP2 is a member of the inner mitochondrial membrane anion carrier superfamily. It is 
known that one mechanism for sensing glucose in pancreatic endocrine ß-cells is 
UCP2-mediated insulin secretion. By mediating mitochondrial proton leakage and decreasing 
ATP production, UCP2 negatively regulates glucose-stimulated insulin secretion. It has been 
proposed that increased UCP2 expression in ß-cells could result in cell dysfunction and the 
development of T2DM. Moreover, gene knockout of UCP2 restores first phase insulin 
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secretion, increases serum insulin levels, and greatly decreases levels of hyperglycemia in 
ob/ob mice. There is also evidence that increased amounts of UCP2 expression in humans can 
downregulate insulin secretion and increase the risk of type 2 diabetes [71]. In conclusion, 
these results suggest that UCP2 negatively regulates glucose-stimulated insulin secretion.  
One study [14] found that genipin could stimulate insulin secretion of pancreatic ß-cells, 
and this effect was dependent on the presence of UCP2. In UCP2-deficient islets, genipin did 
not stimulate insulin secretion. Moreover, genipin increases the mitochondrial membrane 
potential, ATP levels, and closes KATP channels by which genipin ultimately stimulates 
insulin secretion. Genipin also reverses high glucose and obesity induced ß-cell dysfunction 
[14]. Given that genipin is a naturally occurring cross-linking agent by reacting with the 
amino group of proteins, it is theoretically possible that the cross-linking activity of genipin 
could be required for the inhibition of UCP2. However, AG, a genipin derivative that lacks 
protein crosslinking activity, also inhibits UCP2-mediated proton leakage, closes 
KATP-channels, and stimulates insulin secretion in a UCP2-dependent fashion [14]. These 
results suggest that the cross-linking activity of genipin is not required for its biological 
activity as a UCP inhibitor.   
In addition, other findings suggested that genipin has a therapeutic role for type 2 
diabetes patients by improving insulin resistance and augmenting incretin hormone secretion. 
Some studies showed that genipin ameliorates age-related insulin resistance through 
inhibiting hepatic oxidative stress and mitochondrial dysfunction [72]. In another study, 
UCP2-deficient mice had higher plasma levels of the incretin hormone GLP-1 after 
administration of glucose compared with wild-type littermates, which suggested UCP2 may 
serve as a negative regulator of GLP-1 secretion in the gastrointestinal tract. Acute inhibition 
of UCP2 by genipin can improve GLP-1 secretion in ob/ob mice, suggesting that UCP2 
negatively regulates GLP-1 secretion in chronic high-glucose states [73]. Moreover, a study 
showed that genipin is beneficial for treating complications linked to T2DM. A study showed 
that orally administration of genipin significantly ameliorates urinary albumin excretion, 
glomerular basement membrane (GBM) thickness and podocyte injury in diabetic mice. 
Inhibition of UCP2 expression by genipin plays an essential role in halting the progression of 
diabetic nephropathy [74].  
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However, the role of genipin on insulin signal transduction seems to differ in different 
types of cells. In one study, genipin was shown to cause suppression of insulin signal 
transduction via over-activation of c-Jun N-terminal kinase and the subsequent serine 
phosphorylation of the insulin receptor substrate-1 (IRS-1), thus impairing insulin-stimulated 
glucose uptake in 3T3-L1 adipocytes [75]. However, a study In C2C12 myotubes showed 
genipin can stimulate glucose uptake in a time- and dose-dependent manner. In myotubes, 
genipin promoted glucose transporter 4 translocation to the cell surface, and increased the 
phosphorylation of IRS-1, AKT, and GSK3b. Meanwhile, genipin increased ATP levels, 
closed KATP-channels, and increased the concentration of calcium in the cytoplasm in C2C12 
myotubes. Moreover, the Genipin-stimulated glucose uptake could be blocked by both the 
PI3-K inhibitor wortmannin and the calcium chelator EGTA [76]. With these contradictory 
reports, the role of genipin in insulin resistance needs to be further explored. 
Additional benefits of UCP2 activation: UCP2 is also expressed in the brain and 
uncouples ATP production from glucose oxidation in mitochondria to reduce oxidative stress, 
resulting in enhanced mitochondrial function and increased energy metabolism. UCP2 is 
important in the prevention of excessive generation of ROS in mitochondria, transfer of 
mitochondrial substrates, mitochondrial calcium uniport and in the regulation of 
thermogenesis [77]. Mitochondrial dysfunction is involved in the pathogenesis of 
neurodegenerative diseases. Increasing evidence indicates that neuronal UCP2 may well play 
a crucial role in neuronal survival when under stress, and numerous studies link UCP2 to the 
protection of neurons from mitochondrial dysfunction and oxidative damage in various mouse 
models of acute stress and neurodegeneration [78], including PD [79] and AD [80]. 
 
6. Conclusion and future studies 
This review gives an overview of the data published on the pharmacological activity of 
genipin, its anti-inflammatory, neuroprotective and neuritogenic properties, antidiabetic and 
antidepressant effects that may be the basis of the pharmacological effects of genipin on 
neurodegenerative diseases. Thus, genipin shows therapeutic potential for central 
neurodegenerative diseases. However, compared with numerous results published from in 
vitro studies, genipin has not been examined in detail for its neuroprotective roles in in vivo 
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and in clinical studies. In addition, in regard to the inhibition of UCP2 by genipin, there are 
some uncertainties about the pharmacological application of genipin in neurodegenerative 
diseases. In conclusion, the degree of neuroprotection in vivo conferred by genipin needs 
further investigation by testing various animal diseases models. Furthermore, more work is 
required on identifying target molecules of genipin that are involved in signaling pathways 
that modulate neurotrophic activity. 
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Figure 1：The pharmacological effects of genipin on neurodegenerative diseases 
Geniposide is the main effective ingredient in the pharmacological preparations of Gardenia fruit. 
Geniposide is hydrolyzed into genipin by β-D-glucosidases in the intestine. Then, genipin is 
absorbed into the blood circulation to exert pharmacological effect in the body. Genipin may 
inhibit topical and systematic inflammation by inhibiting the expression of inducible NOS and the 
production of NO, inhibition of NF-κB activation, upregulation of HO-1, as well as the decrease 
of proinflammatory cytokines in macrophage. Genipin can stimulate insulin secretion of 
pancreatic ß-cells and improve insulin resistance by inhibition of UCP2, which explains genipin’s 
antidiabetic action. Genipin can cross the blood brain barrier (BBB) and can inhibit the 
neuroinflammation response by inhibiting activation of glia cells and production of 
proinflammatory cytokines. Genipin shows antidepressant effects by promoting expression of 
neurotrophin and inhibiting MAO-B to increase the levels of 5-HT. Genipin also has neurotrophic 
and neuritogenic effects which involves activating neuronal NOS. In addition, genipin may be a 
free radical scavenger and can protects neuronal cells against cytotoxicity induced by various 
neurotoxic agents including amyloid-β (Aβ), 6-OHDA, hydrogen peroxide, and endoplasmic 
reticulum stress inducers. Based on these versatile pharmacological effects, genipin shows 
therapeutic potential for treating central neurodegenerative diseases.  
